Drugs / F2B22E/DL001Z
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05823974 | Apr 2023 → Jul 2024 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F2B22E/DL001Z | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05823974 ↗ |
| Known as | GSKVx000000040677 | “YA participants received a single dose of Flu mRNA study intervention F2B22E/DL001Z (GSKVx000000040677) administered in Phase 1, at Day 1.” NCT05823974 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based Multivalent Seasonal Influenza Vaccine Candidates” NCT05823974 ↗ |
| Route | Intramuscular | “Study intervention was administered intramuscularly in Phase 1, at Day 1.” NCT05823974 ↗ |